MedDRA preferred term · inflammation of blood vessels

Vasculitis: adverse event reports recording this term

11,452 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

11,452
reports recording the term: 0.1% of all reports; 685
reports, 12 months to June 2026: 640 in the 12 months before; 92.6%
marked serious by the reporter: 57.4% across all reports; 7.3%
record death among outcomes, as reported: 9.1% across all reports

"Vasculitis" (in plain words, inflammation of blood vessels) is a MedDRA preferred term recorded in 11,452 adverse event reports received by FDA, 0.1% of the database, from January 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

685 reports recorded it in the 12 months to June 2026, close to the 640 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 92.6% are marked serious, 7.3% include death among the outcomes and 46.1% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Prednisone, Humira and Apixaban. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Prednisone	Corticosteroid	852	0.5%
Humira	—	576	0.1%
Apixaban	Factor Xa inhibitor	548	1.2%
Rituximab	CD20-directed cytolytic antibody	522	0.3%
Hydrochlorothiazide	Thiazide diuretic	514	2.3%
Candesartan	Angiotensin 2 receptor blocker	462	4.5%
Methotrexate	Folate analog metabolic inhibitor	456	0.2%
Albuterol	beta2-Adrenergic agonist	453	2.5%
Levothyroxine sodium	l-Thyroxine	444	3.1%
Nucala	Interleukin-5 antagonist	438	1.4%
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	424	1.9%
Simvastatin	HMG-CoA reductase inhibitor	423	1.2%
Lansoprazole	Proton pump inhibitor	416	1.6%
Naproxen	Nonsteroidal anti-inflammatory drug	402	1.7%
Azathioprine	Purine antimetabolite	399	1.2%
Felodipine	Dihydropyridine calcium channel blocker	392	19.1%
Digoxin	Cardiac glycoside	390	2.5%
Enbrel	Tumor necrosis factor blocker	388	0.1%
Linagliptin	Dipeptidyl peptidase 4 inhibitor	379	13.6%
Isosorbide mononitrate	Nitrate vasodilator	377	11.9%
Budesonide	Corticosteroid	368	2.5%
Isosorbide dinitrate	Nitrate vasodilator	366	27.7%
Imdur	—	356	41.8%
Astrazeneca Covid-19 Vaccine	—	338	35.5%
Bisoprolol fumarate	beta-Adrenergic blocker	313	3.8%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Corticosteroid	2,561	0.3%	0%
Proton pump inhibitor	1,264	0.3%	0%
Tumor necrosis factor blocker	1,124	0.1%	0.1%
Factor Xa inhibitor	878	0.3%	0.1%
Nonsteroidal anti-inflammatory drug	872	0.2%	0%
Angiotensin 2 receptor blocker	835	0.3%	0%
Cephalosporin antibacterial	764	1.3%	0.2%
beta2-Adrenergic agonist	764	0.8%	0.3%
Nitrate vasodilator	753	6.3%	1%
CD20-directed cytolytic antibody	720	0.2%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.3%31

2 to 111.1%130

12 to 171.4%158

18 to 4414%1,604

45 to 6427%3,093

65 to 7414.7%1,685

75 and over10.3%1,185

Age not given31.1%3,566

Patient sex

Female53.6%6,139

Male34.5%3,949

Not given11.9%1,364

Grey bar: all 20,646,523 reports in the database. 30% of these reports give the United States as the country.

Questions about "Vasculitis"

What does "Vasculitis" mean in an adverse event report?

In plain language: inflammation of blood vessels. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record vasculitis?

11,452 reports through June 2026 (0.1% of all reports), 685 of them in the latest 12 months.

Which drugs appear most often in these reports?

Prednisone (852), Humira (576), Apixaban (548), Rituximab (522) and Hydrochlorothiazide (514). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.